Stem Cell Therapy for Bone Degeneration and Cartilage Degeneration is under clinical development by Bioinova and currently in Phase II for Cartilage Degeneration. According to GlobalData, Phase II drugs for Cartilage Degeneration does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Stem Cell Therapy for Bone Degeneration and Cartilage Degeneration LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stem Cell Therapy for Bone Degeneration and Cartilage Degeneration overview
Stem cell therapy is under development for the treatment of knee cartilage degeneration. It constitutes autologous mesenchymal cells. The therapeutic candidate is developed based on cellular therapy technology platform. It is administered through intracartilaginous route.
It was also under development for the treatment of bone degeneration (bone defects).
Bioinova overview
Bioinova operates in pharmaceutical and healthcare industry. It is headquartered in Czech Republic.
For a complete picture of Stem Cell Therapy for Bone Degeneration and Cartilage Degeneration’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
